| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T256 |
0-94 |
Sentence |
denotes |
• Statin therapy and impact on inflammation and patient prognosis • Retrospective cohort study |
| T257 |
95-143 |
Sentence |
denotes |
• Primary endpoint of 28-day all-cause mortality |
| T258 |
144-194 |
Sentence |
denotes |
• Secondary endpoint included acute cardiac injury |
| T259 |
195-217 |
Sentence |
denotes |
• N = 1219 statin use |
| T260 |
218-267 |
Sentence |
denotes |
• N = 12, 762 no statin • In-hospital statin use |
| T261 |
268-289 |
Sentence |
denotes |
• Atorvastatin 83.2%, |
| T262 |
290-310 |
Sentence |
denotes |
• Rosuvastatin 15.6% |
| T263 |
311-521 |
Sentence |
denotes |
• Dose differences between statins were converted to a daily equivalent dose of atorvastatin ranging from 18.9–20.0 mg/day • Reduced all-cause mortality with statin use hazard ratio (HR) 0.63 (95% CI 0.48–0.84) |
| T264 |
522-632 |
Sentence |
denotes |
• Patients on ACEi/ARB therapy in addition to statin did not have increased mortality compared to statin alone |
| T265 |
633-690 |
Sentence |
denotes |
• Statin therapy not associated with acute cardiac injury |
| T266 |
691-971 |
Sentence |
denotes |
• Inflammatory markers CRP, IL-6 were lower in statin treated patients while in hospital • Reduced mortality and improved prognosis associated with in-hospital statin use may be due to the anti-inflammatory and immunomodulatory effects of statins (Zhang, Qin, Cheng, et al., 2020) |
